

Substances were ordinarily ranked based on their total score, with radionuclides and nonradionuclides ranked separately. The 470 candidate substances considered for the Priority List of Hazardous Substances at DOE NPL sites are those substances present at 22 DOE NPL sites, as indicated in site file documents. The 22 sites consist of 134 operable units.

The 22 DOE NPL sites included in this listing activity are as follows: Bonneville Power Authority; Brookhaven National Laboratory; Fernald Environmental Management Project; Hanford 100; Hanford 200; Hanford 300; Hanford 1100; Idaho National Engineering Laboratory; Lawrence Livermore National Laboratory—Site 300; Lawrence Livermore National Laboratory—Main Site; Los Alamos National Laboratory; Maywood Interim Storage Site; Monticello Mine Tailings; Mound Plant; Oak Ridge Reservation; Paducah Gaseous Diffusion Plant; Pantex; Portsmouth Gaseous Diffusion Plant; Rocky Flats Plant; Savannah River Site; WR Grace/Wayne Interim Storage Site; and Weldon Springs Site.

This priority list includes 50 radionuclide and 150 non-radionuclide substances that ATSDR has determined pose the most significant potential threat to human health. All candidate substances have been analyzed and ranked with the algorithm described previously. Substances on this priority list may become the subject of toxicological profiles prepared by ATSDR.

Dated: July 18, 1996.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

The top 20 radionuclides and top 20 nonradionuclides on the Priority List of Hazardous Substances at DOE NPL Sites are as follows:

Radionuclides:

- 1 THORIUM-232
- 2 URANIUM-235
- 3 RADIUM-228
- 4 URANIUM-238
- 5 RADIUM-226
- 6 COBALT-60
- 7 KRYPTON-85
- 8 AMERICIUM-241
- 9 URANIUM-234
- 10 POTASSIUM-40
- 11 EUROPIUM-152
- 12 NEPTUNIUM-237
- 13 CESIUM-137
- 14 PROTACTINIUM-231
- 15 STRONTIUM-90
- 16 KRYPTON-88
- 17 THALLIUM-208
- 18 THORIUM-228

19 PROTACTINIUM-234

20 ARGON-41

NonRadionuclides:

- 1 LEAD
- 2 ARSENIC
- 3 MERCURY, METALLIC
- 4 AROCLOR 1254
- 5 BENZO(B)FLUORANTHENE
- 6 BENZO(A)PYRENE
- 7 AROCLOR 1248
- 8 CADMIUM
- 9 BERYLLIUM
- 10 PHOSPHORUS
- 11 VINYL CHLORIDE
- 12 AROCLOR 1260
- 13 POLYCHLORINATED BIPHENYLS
- 14 CHLOROFORM
- 15 DIBENZO(A,H)ANTHRACENE
- 16 DIELDRIN
- 17 MANGANESE
- 18 CYANIDE
- 19 NICKEL
- 20 BENZENE

[FR Doc. 96-18766 Filed 7-23-96; 8:45 am]

BILLING CODE 4163-70-P

Centers for Disease Control and Prevention

Translation Advisory Committee for Diabetes Prevention and Control Programs: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Translation Advisory Committee for Diabetes Prevention and Control Programs.

Times and Dates: 8:30 a.m.-4:30 p.m., August 15, 1996. 8:30 a.m.-3 p.m., August 16, 1996.

Place: Decatur Holiday Inn Hotel and Conference Plaza, 130 Clairemont Avenue, Decatur, Georgia 30030, telephone 404/371-0204.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: This committee is charged with advising the Director, CDC, regarding policy issues and broad strategies for diabetes translation activities and control programs designed to reduce risk factors, health services utilization, costs, morbidity, and mortality associated with diabetes and its complications. The Committee identifies research advances and technologies ready for translation into widespread community practice; recommends broad public health strategies to be implemented through public health interventions; identifies opportunities for surveillance and epidemiologic assessment of diabetes and related complications; and for the purpose of assuring the most effective use and organization of resources, maintains liaison and coordination of programs within the

Federal, voluntary, and private sectors involved in the provision of services to people with diabetes.

Matters to be Discussed: Committee members will discuss assessment of CDC's State Diabetes Control Programs, the status of the National Diabetes Education Program, and goals and future areas of emphasis for the Division of Diabetes Translation.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Cheryl Shaw, Program Specialist, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE, M/S K-10, Atlanta, Georgia 30341-3724, telephone 770/488-5004.

Dated: July 18, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-18768 Filed 7-23-96; 8:45 am]

BILLING CODE 4163-18-M

Administration for Children and Families

[Program Announcement No. OCS-96-08A]

Notice of Clarification of Applicant Eligibility Under the Request for REACH Plans Under the Office of Community Services' FY 1996 Low-Income Home Energy Assistance Program, Residential Energy Assistance Challenge Option (REACH) Program

AGENCY: Office of Community Services, ACF, DHHS.

ACTION: Notice.

SUMMARY: This is a Clarification of Applicant Eligibility under Program Announcement No. OCS-96-08 (61 FR 35518-35545) for the Office of Community Services' Residential Energy Assistance Challenge Option (REACH) Program. The Administration for Children and Families (ACF), Office of Community Services (OCS) wishes to make clear that "community-based nonprofit entities" which are to be the CBO Recipients through which REACH services are to be delivered pursuant to Section 2607B(e) of the Low-Income Home Energy Assistance Act of 1981, as amended, 42 U.S.C. 8621 *et seq.*, includes those organizations described in section 673 of the Community Services Block Grant Act (42 U.S.C. 9902(1)) which are public agencies, that is, a department, agency or unit of local government.

FOR FURTHER INFORMATION CONTACT: Office of Community Services, Administration for Children and Families, Division of Community

Demonstration Programs, 370 L'Enfant Promenade, S.W., Fifth Floor, Washington, D.C. 20447, Attention: Richard Saul—(202) 401-9341; Anna Guidery—(202) 401-5318.

This Notice is accessible on the OCS Electronic Bulletin Board for downloading through your computer modem by calling 1-800-627-8886. For assistance in accessing the Bulletin Board, a Guide to Accessing and Downloading is available from Ms. Minnie Landry at (202) 401-5309.

The Catalog of Federal Domestic Assistance number for this program is 93.568.

I. Clarification of Definition

A. Section 2607B(e)(2)(A) of the Low-Income Home Energy Assistance Act of 1981, as amended, requires that each State REACH Plan include "an assurance that such State will deliver services through community-based nonprofit entities in such State * * *"

B. Section 2607B(e)(2)(B) requires that "in awarding grants or entering into contracts to carry out its REACH initiative, the State will give priority to organizations that—

(i) are described in section 673 of the Community Services Block Grant Act (42 U.S.C. 6863 *et seq.*) * * *" That is, priority is to be given to Community Action Agencies. (This is one of three criteria for priority consideration.)

C. In its Program Announcement of July 5, 1996 (OCS-96-08), 61 FR 35518-35545, OCS included a definition of "Community-based, nonprofit" that defined it as "a corporation or association * * *" which has caused some confusion among prospective applicants as to whether a public Community Action Agency which is a unit of local government is eligible to be the "community-based nonprofit entity" through which REACH services are to be delivered. The answer is yes. "Community-based nonprofit entities" includes organizations described in section 673 of the Community Services Block Grant Act that are public agencies or entities such as public Community Action Agencies that are a unit of local government.

Dated: July 19, 1996.

Donald Sykes,

Director, Office of Community Services.

[FR Doc. 96-18830 Filed 7-23-96; 8:45 am]

BILLING CODE 4184-01-P

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Advisory Committee for Pharmaceutical Science (formerly Generic Drugs Advisory Committee)

Date, time, and place. August 15, 1996, 8 a.m., and August 16, 1996, 7:30 a.m., Holiday Inn—Gaithersburg, Goshen Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, August 15, 1996, 8 a.m. to 1 p.m.; open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion, 2 p.m. to 6:30 p.m.; open committee discussion, August 16, 1996, 7:30 a.m. to 10 a.m.; Kimberly L. Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Advisory Committee for Pharmaceutical Science, code 12539. Please call the hotline for

information concerning any possible changes.

General function of the committee. The committee gives advice on scientific and technical issues concerning the safety and effectiveness of human generic drug products for use in the treatment of a broad spectrum of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before August 1, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On August 15, 1996, the committee will discuss the Biopharmaceutics Drug Classification System and Individual Bioequivalence. On August 16, 1996, the committee will discuss Product Quality Research, Laboratory-Based Clinical Pharmacology Research, and Clinic-Based Clinical Pharmacology Research.

Joint Meeting of the Advisory Committee for Pharmaceutical Science and the Pulmonary and Allergy Drugs Advisory Committee

Date, time, and place. August 16, 1996, 10 a.m., Holiday Inn—Gaithersburg, Goshen Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, 10 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12:30 p.m., unless public participation does not last that long; open committee discussion, 12:30 p.m. to 3:30 p.m.; Kimberly L. Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Advisory Committee for Pharmaceutical Science, code 12539. Please call the hotline for information concerning any possible changes.

General function of the committees. The Advisory Committee for Pharmaceutical Science gives advice on scientific and technical issues concerning the safety and effectiveness of human generic drug products for use in the treatment of a broad spectrum of